欢迎访问浙江中西医结合杂志   今天是   加入收藏   |   设为首页
张莉莉,李月翠,李成行,胡伟跃.活血软坚方对慢性乙型肝炎患者肝纤维化疗效及T淋巴细胞亚群影响[J].浙江中西医结合杂志,2020,30(10):
活血软坚方对慢性乙型肝炎患者肝纤维化疗效及T淋巴细胞亚群影响
Therapeutic effect of Huoxue Ruanjian recipe and its effect on T lymphocyte subgroup of liver fibrosis patients with Chronic hepatitis BZHANG Lili, LI Yuecui, LI Chenghang, HU Weiyue. Department of Infections, Yongkang First People’s Hospital, Yongkang,321300, China
投稿时间:2020-04-13  修订日期:2020-05-18
DOI:
中文关键词:  活血软坚  慢性乙型肝炎  肝纤维化  T淋巴细胞亚群
英文关键词:Huoxue Ruanjian recipe  Chronic hepatitis b  Liver fibrosis  Invigorate the blood  T lymphocyte subsets
基金项目:浙江省医药卫生科技计划项目(2019KY764)
作者单位E-mail
张莉莉 永康市第一人民医院 永康 321300 ykzhangll123@163.com 
李月翠 永康市第一人民医院 li15168012476@126.com 
李成行 永康市第一人民医院  
胡伟跃 永康市第一人民医院  
摘要点击次数: 117
全文下载次数: 0
中文摘要:
      目的:观察活血软坚方联合西医治疗对慢性乙型肝炎(CHB)肝纤维化患者中医症候、肝功能、肝纤维化、T淋巴细胞亚群及临床疗效影响。方法:以我院2018年1月-2019年6月收治的100例CHB肝纤维化患者为研究对象,随机分为两组,最终对照组(47例)给予恩替卡韦+双环醇治疗,研究组(50例)在对照组基础上加用活血软坚方治疗,疗程48周。比较治疗前、48周时两组患者中医症候积分,肝功能、肝纤维相关指标,T淋巴细胞亚群;并记录临床疗效及不良反应。结果:48周时,两组患者中医症候积分,肝功能指标(ALT、AST、GGT、TBIL),肝纤维指标(Ⅳ-C、PCⅢ、LN、HA)均明显下降(P<0.01)。且两组患者CD3+、CD4+、CD4+/CD8+明显升高(P<0.01),CD8+明显下降(P<0.01)。两组比较,研究组上述指标均改善更明显(P<0.05),临床疗效更高(P<0.05)。两组患者治疗期间均未发生药物不良反应。结论:活血软坚方联合西医治疗CHB肝纤维化具有协同作用,改善患者临床症候表现,调节肝功能及免疫功能,降低肝纤维化水平,提高治疗疗效,且安全性高,值得临床进一步推广。
英文摘要:
      Objective: To observe the effects of Huoxue Ruanjian recipe combined with western medicine on TCM symptoms, liver function, liver fibrosis, T lymphocyte subgroup and clinical efficacy in liver fibrosis patients with chronic hepatitis b(CHB). Methods: 100 cases of CHB patients were randomly divided into two groups, 47 cases were included in the control group and 50 cases were included in the intervention group. The control group was treated with entecavir + dicyclol alcohol, and the research group was treated with Huoxue Ruanjian recipe on the basis of the control group. The course of treatment was 48 weeks. The scores of TCM symptoms, liver function, liver fiber indexes, and T lymphocyte subsets of the two groups were compared before treatment and at 48 weeks. Clinical efficacy and adverse reactions were also recorded. Results: after 48 weeks, two groups of patients with symptoms integral, the liver function index (ALT, AST, GGT, TBIL), liver fiber each index (Ⅳ- C, PC Ⅲ, LN and HA) were significantly decreased (P<0.01). At the same time, after 48 weeks, CD3+, CD4+ and CD4+/CD8+ in the two groups increased significantly (P<0.01), and CD8+ decreased significantly (P<0.01). Compared with the two groups, the above indicators in the study group improved more significantly (P<0.05), and the clinical efficiency was higher (P<0.05). No adverse drug reactions occurred during treatment in both groups. Conclusion: Huoxue Ruanjian recipe combined with western medicine in the treatment of liver fibrosis patients with CHB, which can improve the clinical symptoms, regulate the liver function and immune function, reduce the level of liver fibrosis, improve the therapeutic effect, and be worthy of further clinical promotion.
查看全文  查看/发表评论  下载PDF阅读器
关闭